Articles by Haley Schuster, MD

Exploring CBT Approaches for Chronic Insomnia in Adults: A Systematic Review and Network Meta-Analysis
ByMohan Palakollu, MD,Grethel Perez Meek, DO,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Discover the most effective components of cognitive behavioral therapy for chronic insomnia, enhancing treatment outcomes and patient care strategies.

Evaluating the Efficacy of CBT Plus Psychopharmacology vs Psychopharmacology Alone in the Treatment of Adult ADHD
ByYazan Al-Khalila, MD,Hesham Essa, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Cognitive Effects of Antidepressant Pharmacotherapy in Late-Life Depression
ByLior Hilsenrath, MD,Kari Wolatz, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

Social Media Use in Older Adults May Promote Positive Psychosocial Outcomes
ByMeagan Kubista, MD,Orrin Chambers, DO,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

Antipsychotics and the QTc Interval During Delirium in the Intensive Care Unit: A Secondary Analysis of a Randomized Clinical Trial
ByJoshua Robak, MD,Nishi Modi, MBBS,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Benzodiazepine Discontinuation Associated With Increased Mortality in Patients on Stable, Long-Term Benzodiazepines
ByGeena Sutherland, MD,Nancy Kartiko, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP New research reveals that discontinuing long-term benzodiazepine therapy may increase risks of mortality and other adverse outcomes, challenging common assumptions.

Clinical Features Associated With Response to Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
ByJustin Allen, MD,Lalangi Marasinghe, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Ketamine or ECT? A new study reveals which works best for severe depression—depending on the patient and setting.

Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia
ByCaitlin Leconte, MD,Albert Dickan, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.

Evaluating the Efficacy of TMS for the Treatment of OCD
ByTommy Sung, MD,Coralie Eilers, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Clinicians should consider rTMS as an intervention to alleviate OCD symptoms, especially in those who have failed other treatments or those with comorbid depression.

Assessing the Effectiveness of Treatments of Personality Disorders in the Community
ByAnvesh Jalasutram, MD,Ayse Coskun, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP Patients with personality disorders would benefit from therapy regardless of modality, duration, or intensity.

Exploring the Antisuicidal Effects of Lithium
ByJesse Woo, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

TMS for the Treatment of OCD
ByTommy Sung, MD,Coralie Eilers, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP A new study shows that rTMS has moderate therapeutic effects on OCD severity.

Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use
ByMasha Impallaria, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.